OrthoAccel Technologies announces the availability of new Continuing Education course

OrthoAccel Technologies, Inc., developers of the AcceleDent System, which is an acceleration device to enhance orthodontics, announced the availability of a new Continuing Education course published by PennWell Corporation, a leader in professional education for many industries, including medicine and dentistry. The course focuses on patient views about orthodontic treatment, a summary of treatment biomechanics, factors that increase treatment duration, and the role that pulsatile forces can play in modulating periodontal biology and accelerating orthodontic treatment. The technology supporting the AcceleDent System involves the application of pulsatile forces. The course can be accessed directly through PennWell's dental education website http://www.ineedce.com/

AcceleDent is a simple, removable dental device that an orthodontic patient wears in the mouth for 20 minutes daily to accelerate orthodontic tooth movement. A Phase I clinical trial in 2008 in Houston, Texas demonstrated the safety of the device. The first case in private practice was initiated in October 2009 in the UK, following EU approval.

The course is a peer-reviewed publication titled "Advances in Orthodontic Treatment," and was authored by Jeremy J. Mao, DDS, PhD, who recently lectured internationally on the biological action of pulsatile force, and Chung H. Kau, DDS, MScD, MBA, PhD, MOrth, FDS, FFD (Ortho), FAMS (Ortho), who oversaw the Phase I clinical trial that featured the first use of the AcceleDent technology in patients at the University of Texas Dental Branch. The course is intended for orthodontists and dental professionals and awards 4 CE credits. PennWell is an ADA CERP (Continuing Education Recognition Program) provider.

Dr. Jeremy Mao observed, "We believe that a great deal of knowledge has been unveiled in recent years as it relates to pulsatile forces and biological response of alveolar bone. The scientific data have important implications in the rate of orthodontic treatment. This course is a timely opportunity to create awareness around these concepts." He continued, "The Phase I clinical trial conducted at the University of Texas Dental Branch represents scientific validation of years of animal data on the effectiveness of pulsatile forces." Brent Tarver, VP Clinical Affairs for the Company added, "OrthoAccel is committed to its investment in a clinical strategy that is ultimately intended to not only elaborate the scientific basis for AcceleDent, but also discover new ways to improve orthodontic care."

OrthoAccel is presently controlling availability of AcceleDent in the UK to a select group of orthodontic specialists before a broader release there in October 2010.